PTC/SB/08x (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2008 CMB 0851-02
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMEN
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMEN
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb

	Application Number				
	Filing Date				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Jeffre		rey D. Edwards		
(Not for submission under 37 CFR 1.99)	Art Unit				
,,	Examiner Name				
	Attorney Docket Number	er .	81443-2		

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines wher nt Passages or Rele s Appear	
	1	6574504	B1	2003-06	6-03	A. Mazaury et	al.			
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines wher nt Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publ	shed Ap	plication	citation	n information p	lease click the Ad	d button		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or v	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	1
	1	2307862	GB		A	1999-06-11	JEHAN			
	2	2000003762	wo		A1	2000-01-27	MAZAURY			
	3	1996015829	wo		A2	1996-05-30	ADVATECH CORPORATION			Г

	Application Number				
NEODIA TION DIOOL COURT	Filing Date				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Jeffre		ey D. Edwards		
(Not for submission under 37 CFR 1.99)	Art Unit				
,	Examiner Name				
	Attorney Docket Numb	er	81443-2		

If you wisl	h to a	id add	ditional Fo	reign Pa	atent [Docur	ment o	citation	infor	mation	please	click th	e Add b	utton	Add			
					NC	ON-P	ATEN	IT LITE	RAT	URE D	OCUM	ENTS			Remo	ve		
Examiner Initials*	Cite No	(bool	ude name k, magazi isher, city	ne, journ	nal, se	erial, s	sympo	osium,	catak									Тъ
	1																	
If you wis	h to a	id add	ditional no	n-paten	t litera	ature o	docum	nent ci	tation	inform	ation pl	ease cli	ck the A	Add b	utton	Add		
							EX/	AMINE	R SIC	SNATU	RE							
Examiner	Signa	ture										Date Co	onsiden	ed				
*EXAMIN citation if																	ough a	

1 See Kint Cote of USPTO Patent Documents at year, USPTO_GOLY or MEPP 910.4. Faiter office that issued the document, by the how-letter code (WIPO Standard ST.3.) Fair Judgeneese plant for connents, the decision to the year of the reight on the Engeror must precise the serial number of the plant forcement.

1 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if youselbe. 3 Applicant is to place a check mark here (Engint) fairguing entriations a statistical.

Application Number Filing Date Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date First Number Inventor Jettrey D. Edwards Art Unit Examiner Name Attorney Cooket Number | 81443.2

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) for the contraction of th

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

.7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/George C. Rondeau, Jr., Reg. No. 28893/	Date (YYYY-MM-DD)	2006-05-22
Name/Drint	Coorno C Bondoou Ir	Registration Number	28803

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2.11.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.